Stem Cell Therapies for Reversing Vision Loss

Trends in Biotechnology

Volumn 35, Issue 11, 2017, Pages 1102-1117

  Higuchi, Akon ^a,b,c,d   Kumar, S Suresh ^e   Benelli, Giovanni ^f,g   Alarfaj, Abdullah A ^b   Munusamy, Murugan A ^b   Umezawa, Akihiko ^c   Murugan, Kadarkarai ^h,i  

^a NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d RIKEN   (Japan)

^e UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^f UNIVERSITY OF PISA   (Italy)

^g SCUOLA SUPERIORE SANT ANNA   (Italy)

^h BHARATHIAR UNIVERSITY   (India)

ⁱ THIRUVALLUVAR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDES; CELLS; CYTOLOGY; DISEASE CONTROL; OPHTHALMOLOGY; PATIENT TREATMENT; POLYMERS; STEM CELLS;

ADIPOSE DERIVED STEM CELLS; DIFFERENTIATED CELLS; DISEASE TREATMENT; MACULAR DEGENERATION; MESENCHYMAL STEM CELL; MONONUCLEAR CELLS; PLURIPOTENT STEM CELLS; RETINAL PIGMENT EPITHELIUM;

CELL CULTURE;

BIOMATERIAL;

AGE RELATED MACULAR DEGENERATION; BIOENGINEERING; BONE MARROW DERIVED MONONUCLEAR CELL; CELL DIFFERENTIATION; FETAL STEM CELL; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RETINAL PIGMENT EPITHELIUM; RETINITIS PIGMENTOSA; REVIEW; STARGARDT DISEASE; STEM CELL TRANSPLANTATION; VISUAL IMPAIRMENT; ANIMAL; BLINDNESS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; TRANSPLANTATION;

ANIMALS; BLINDNESS; CELL DIFFERENTIATION; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PLURIPOTENT STEM CELLS; RETINAL PIGMENT EPITHELIUM;

EID: 85025475102     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2017.06.016     Document Type: Review

References (57)

1. Kriks, S., et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480 (2011), 547–551.
2. Gonzalez, R., et al. Deriving dopaminergic neurons for clinical use. A practical approach. Sci. Rep., 3, 2013, 1463.
3. Lippmann, E.S., et al. Defined human pluripotent stem cell culture enables highly efficient neuroepithelium derivation without small molecule inhibitors. Stem Cells 32 (2014), 1032–1042.
4. Kamao, H., et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Rep. 2 (2014), 205–218.
5. Schwartz, S.D., et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 385 (2015), 509–516.
6. Idelson, M., et al. Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. Cell Stem Cell 5 (2009), 396–408.
7. Buchholz, D.E., et al. Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. Stem Cells 27 (2009), 2427–2434.
8. Burridge, P.W., et al. Chemically defined generation of human cardiomyocytes. Nat. Methods 11 (2014), 855–860.
9. Tasnim, F., et al. Cost-effective differentiation of hepatocyte-like cells from human pluripotent stem cells using small molecules. Biomaterials 70 (2015), 115–125.
10. Pagliuca, F.W., et al. Generation of functional human pancreatic beta cells in vitro. Cell 159 (2014), 428–439.
11. Rezania, A., et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol. 32 (2014), 1121–1133.
12. Schwartz, S.D., et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379 (2012), 713–720.
13. Kimbrel, E.A., Lanza, R., Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat. Rev. Drug Discov. 14 (2015), 681–692.
14. Sivan, P.P., et al. Stem cell therapy for treatment of ocular disorders. Stem Cells Int., 2016, 2016, 8304879.
15. Song, W.K., et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Rep. 4 (2015), 860–872.
16. Mandai, M., et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 376 (2017), 1038–1046.
17. Higuchi, A., et al. Generation of pluripotent stem cells without the use of genetic material. Lab. Invest. 95 (2015), 26–42.
18. Carr, A.J., et al. Development of human embryonic stem cell therapies for age-related macular degeneration. Trends Neurosci. 36 (2013), 385–395.
19. Nazari, H., et al. Stem cell based therapies for age-related macular degeneration: the promises and the challenges. Prog. Retin. Eye Res. 48 (2015), 1–39.
20. Pennington, B.O., Clegg, D.O., Pluripotent stem cell-based therapies in combination with substrate for the treatment of age-related macular degeneration. J. Ocul. Pharmacol. Ther. 32 (2016), 261–271.
21. Ramsden, C.M., et al. Stem cells in retinal regeneration: past, present and future. Development 140 (2013), 2576–2585.
22. Zarbin, M., Cell-based therapy for degenerative retinal disease. Trends Mol. Med. 22 (2016), 115–134.
23. Higuchi, A., et al. Design of polymeric materials for culturing human pluripotent stem cells: progress toward feeder-free and xeno-free culturing. Prog. Polym. Sci. 39 (2014), 1348–1374.
24. Higuchi, A., et al. Physical cues of biomaterials guide stem cell differentiation fate. Chem. Rev. 113 (2013), 3297–3328.
25. Chen, Y.M., et al. Xeno-free culture of human pluripotent stem cells on oligopeptide-grafted hydrogels with various molecular designs. Sci. Rep., 7, 2017, 45146.
26. Higuchi, A., et al. Polymeric design of cell culture materials that guide the differentiation of human pluripotent stem cells. Prog. Polym. Sci. 65 (2017), 83–126.
27. Kao, T., et al. Suppression of cancer-initiating cells and selection of adipose-derived stem cells cultured on biomaterials having specific nanosegments. J. Biomed. Mater. Res. B 102 (2014), 463–476.
28. Meng, Q.Y., et al. The differentiation and isolation of mouse embryonic stem cells toward hepatocytes using galactose-carrying substrata. Biomaterials 33 (2012), 1414–1427.
29. Lin, H.R., et al. Purification and differentiation of human adipose-derived stem cells by membrane filtration and membrane migration methods. Sci. Rep., 7, 2017, 40069.
30. Higuchi, A., et al. A hybrid-membrane migration method to isolate high-purity adipose–derived stem cells from fat tissues. Sci. Rep., 5, 2015, 10217.
31. Chen, D.C., et al. Purification of human adipose-derived stem cells from fat tissues using PLGA/silk screen hybrid membranes. Biomaterials 35 (2014), 4278–4287.
32. Hsiung, J., et al. Polarized human embryonic stem cell-derived retinal pigment epithelial cell monolayers have higher resistance to oxidative stress-induced cell death than nonpolarized cultures. Stem Cells Transl. Med. 4 (2015), 10–20.
33. Rose, J.B., et al. Gelatin-based materials in ocular tissue engineering. Materials 7 (2014), 3106–3135.
34. Tao, S., et al. Survival, migration and differentiation of retinal progenitor cells transplanted on micro-machined poly(methyl methacrylate) scaffolds to the subretinal space. Lab Chip 7 (2007), 695–701.
35. Subrizi, A., et al. Generation of hESC-derived retinal pigment epithelium on biopolymer coated polyimide membranes. Biomaterials 33 (2012), 8047–8054.
36. Kearns, V., et al. Plasma polymer coatings to aid retinal pigment epithelial growth for transplantation in the treatment of age related macular degeneration. J. Mater. Sci. Mater. Med. 23 (2012), 2013–2021.
37. Hu, Y., et al. A novel approach for subretinal implantation of ultrathin substrates containing stem cell-derived retinal pigment epithelium monolayer. Ophthalmic Res. 48 (2012), 186–191.
38. Lu, B., et al. Mesh-supported submicron parylene-C membranes for culturing retinal pigment epithelial cells. Biomed. Microdevices 14 (2012), 659–667.
39. Diniz, B., et al. Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer. Invest. Ophthalmol. Vis. Sci. 54 (2013), 5087–5096.
40. Stanzel, B.V., et al. Subretinal delivery of ultrathin rigid-elastic cell carriers using a metallic shooter instrument and biodegradable hydrogel encapsulation. Invest. Ophthalmol. Vis. Sci. 53 (2012), 490–500.
41. Redenti, S., et al. Engineering retinal progenitor cell and scrollable poly(glycerol-sebacate) composites for expansion and subretinal transplantation. Biomaterials 30 (2009), 3405–3414.
42. Redenti, S., et al. Retinal tissue engineering using mouse retinal progenitor cells and a novel biodegradable, thin-film poly(ε-caprolactone) nanowire scaffold. J. Ocul. Biol. Dis. Infor. 1 (2008), 19–29.
43. Stanzel, B.V., et al. Human RPE stem cells grown into polarized RPE monolayers on a polyester matrix are maintained after grafting into rabbit subretinal space. Stem Cell Rep. 2 (2014), 64–77.
44. Kuriyan, A.E., et al. Vision loss after intravitreal injection of autologous ‘stem cells’ for AMD. N. Engl. J. Med. 376 (2017), 1047–1053.
45. Park, S.S., et al. Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Invest. Ophthalmol. Vis. Sci. 56 (2014), 81–89.
46. Otani, A., et al. Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells. J. Clin. Invest. 114 (2004), 765–774.
47. Park, S.S., et al. Long-term effects of intravitreal injection of GMP-grade bone-marrow-derived CD34+ cells in NOD-SCID mice with acute ischemia-reperfusion injury. Invest. Ophthalmol. Vis. Sci. 53 (2012), 986–994.
48. Weiss, J.N., et al. Stem cell ophthalmology treatment study (SCOTS) for retinal and optic nerve diseases: a preliminary report. Neural Regen. Res. 10 (2015), 982–988.
49. Weiss, J.N., et al. Stem cell ophthalmology treatment study (SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy. Neural Regen. Res. 10 (2015), 1507–1515.
50. Tamaki, S.J., et al. Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell 5 (2009), 310–319.
51. McGill, T.J., et al. Transplantation of human central nervous system stem cells – neuroprotection in retinal degeneration. Eur. J. Neurosci. 35 (2012), 468–477.
52. Bongso, A., Fong, C.Y., The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord. Stem Cell Rev. 9 (2013), 226–240.
53. Fan, C.G. et al. Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. Stem Cell Rev. 7, 195–207.
54. Hu, Y., et al. Wharton's jelly mesenchymal stem cells differentiate into retinal progenitor cells. Neural Regen. Res. 8 (2013), 1783–1792.
55. Leow, S.N., et al. Safety and efficacy of human Wharton's jelly-derived mesenchymal stem cells therapy for retinal degeneration. PLoS One, 10, 2015, e0128973.
56. Lin, H.R., et al. Purification and differentiation of human adipose-derived stem cells by membrane filtration and membrane migration methods. Sci. Rep., 7, 2017, 40069.
57. Higuchi, A., et al. A hybrid-membrane migration method to isolate high-purity adipose–derived stem cells from fat tissues. Sci. Rep., 5, 2015, 10217.